Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: Results of a pilot randomized trial

International Journal of Cardiology

Volumn 167, Issue 5, 2013, Pages 2177-2181

  Parri, Maria Serena ^a   Gianetti, Jacopo ^a   Dushpanova, Anar ^c   Della Pina, Francesca ^c   Saracini, Claudia ^b   Marcucci, Rossella ^b   Giusti, Betti ^b   Berti, Sergio ^a  

^a G PASQUINUCCI HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SCUOLA SUPERIORE SANT ANNA   (Italy)

Author keywords

Clopidogrel; CYP2C19*2; Pantoprazole

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; CYTOCHROME P450 2C19; PANTOPRAZOLE; PLACEBO; RANITIDINE;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CYTOCHROME 2C19 GENE; DRUG ANTAGONISM; DRUG INDICATION; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PILOT STUDY; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE FUNCTION ANALYZER;

CLOPIDOGREL; CYP2C19*2; PANTOPRAZOLE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 84883296162     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.05.080     Document Type: Article

References (30)

1. E.M. Antman, D.T. Anbe, and P.W. Armstrong ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction) J Am Coll Cardiol 44 2004 1 211
2. S.R. Mehta, S. Yusuf, and R.J. Peters Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percoutaneous coronary intervention: the PCI-CURE study Lancet 358 2001 527 533
3. S.B. King III, S.C. Smith Jr., and J.W. Hirshfeld Jr. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines J Am Coll Cardiol 51 2008 172 209
4. P.A. Gurbel, and U.S. Tantry Clopidogrel resistance? Thromb Res 120 2007 311 321
5. A.M. Gori, R. Marcucci, and R. Paniccia Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function J Thromb Haemost 100 2008 1136 1145
6. P. Buonamici, R. Marcucci, and A. Migliorini Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis J Am Coll Cardiol 49 2007 2312 2317
7. C. Frere, T. Cuisset, and P.E. Morange Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome Am J Cardiol 101 2008 1088 1093
8. W.C. Lau, P.A. Gurbel, and P.B. Watkins Contribution of hepatic cytocrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171
9. J.P. Collet, J.S. Hulot, and A. Pena Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
10. P. Wenaweser, P. Eshtehardi, and L. Abrecht A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial Thromb Haemost 104 2010 554 562
11. M. Schachter Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update Fundam Clin Pharmacol 19 2005 117 125
12. J.M. Siller-Matula, A.O. Spiel, I.M. Lang, G. Kreiner, G. Christ, and B. Jilma Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 148 2009 e1 e5
13. T. Cuisset, C. Frere, and J. Quilici Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose. The PACA (Proton Pump Inhibitors And Clopidogrel Association) Prospective Randomized Study J Am Coll Cardiol 54 2009 1149 1153
14. M. Gilard, B. Arnaud, and J.C. Cornily Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin. The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study J Am Coll Cardiol 51 2008 256 260
15. D. Trenk, W. Hochholzer, and M.F. Fromm Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
16. B. Giusti, A.M. Gori, and R. Marcucci Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
17. P.M. Ho, T.M. Maddox, and L. Wang Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 301 2009 937 944
18. D. Sibbing, T. Morath, and J. Stegherr Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel Thromb Haemost 101 2009 714 719
19. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientandProviders
20. http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix
21. M.L. O'Donoghue, E. Braunwald, and E.M. Antman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 2009 989 997
22. N.S. Abraham, M.A. Hlatky, and E.M. Antman ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use Am J Gastroenterol 105 2010 2533 2549
23. A.S. Taha, C. McCloskey, R. Prasad, and V. Bezlyak Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial Lancet 374 2009 119 125
24. B. Jilma Platelet function analyzer - PFA-100: a tool to quantify congenital or acquired platelet dysfunction J Lab Clin Med 138 2001 152 163
25. J.L. Reny, P. De Moerloose, M. Dauzat, and P. Fontana Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis J Thromb Haemost 6 2008 444 450
26. R. Paniccia, E. Antonucci, and N. Maggini Light transmittance aggregometry induced by different concentrations of adenosine diphosphate to monitor clopidogrel therapy: a methodological study Ther Drug Monit 33 2011 94 98
27. J. Gianetti, M.S. Parri, and S. Sbrana Platelet activation predicts recurrent ischemic events after percutaneous coronary angioplasty: a 6 months prospective study Thromb Res 118 2006 487 493
28. L. Bonello, U.S. Tantry, and R. Marcucci Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate J Am Coll Cardiol 56 2010 919 933
29. E.R. Bates, W.C. Lau, and D.J. Angiolillo Clopidogrel-drug interactions J Am Coll Cardiol 57 2011 1251 1263
30. D.J. Angiolillo, C.M. Gibson, and S. Cheng Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies Clin Pharmacol Ther 89 2011 65 74